Sort   by:  
 Page size 
UnknownDLG1 functions upstream of SDCCAG3 and IFT20 to control ciliary targeting of polycystin-2
Not available
S-SCDT-10_1038-S44319-024-00170-1 | biostudies-other
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownDelivery of acute ischaemic stroke treatments in the European region in 2019 and 2020.
Not available
S-EPMC10472963 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931 | biostudies-literature
UnknownDexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595 | biostudies-literature
UnknownEffect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
UnknownAspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8598213 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
Sort   by:  
 Page size